Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05106374 · ClinicalTrials.gov registry record
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
A clinical trial of Hematopoietic and Lymphoid Cell Neoplasm and Lung Non-Small Cell Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Active
- Registry status
- 182
- Enrollment target
- 1
- Study location
NCT05106374: Active study of Hematopoietic and Lymphoid Cell Neoplasm and Lung Non-Small Cell Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
NCT05106374 is a study of Hematopoietic and Lymphoid Cell Neoplasm and Lung Non-Small Cell Carcinoma that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 182 participants, below the 951-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05106374, a study of Hematopoietic and Lymphoid Cell Neoplasm and Lung Non-Small Cell Carcinoma, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 182 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial evaluates the risk of chemotherapy toxicity in older patients with blood cancer or non-small cell lung cancer. The purpose of this study is to describe a patient's wellness before and after chemotherapy treatment. This may help researchers better understand patient's ability to tolerate treatment and in the future devise the best treatment for a patient based on their "fitness."
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- PROCEDURE Cognitive Assessment
- OTHER Physical Performance Testing
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT05106374 still lists
NCT05106374 is an observational study that tracks outcomes without assigning an intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 951-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05106374 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05106374 about?
NCT05106374 is a clinical study titled "Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer". This trial evaluates the risk of chemotherapy toxicity in older patients with blood cancer or non-small cell lung cancer. The purpose of this study is to describe a patient's wellness before and after chemotherapy treatment. This may help researchers better understand patient's ability to tolerate t...
What is the current status of trial NCT05106374?
This trial is currently active not recruiting. The enrollment target is 182 participants. The study started on 2018-09-04. Estimated completion is 2025-12-31.
What conditions does trial NCT05106374 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Lung Non-Small Cell Carcinoma.
What interventions are being tested in trial NCT05106374?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Cognitive Assessment (PROCEDURE), Physical Performance Testing (OTHER).
Who is sponsoring clinical trial NCT05106374?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05106374 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05106374's enrollment target sits among peer trials
182 36th of 104 higher than 69 of 104 other Hematopoietic and Lymphoid Cell Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematopoietic and Lymphoid Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
RECRUITING
-
Role of Gut Microbiome in Cancer Therapy
RECRUITING
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Increasing Knowledge and Interest in Cancer Clinical Trials
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI